Upstream Bio (NASDAQ:UPB) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Upstream Bio (NASDAQ:UPB) from a hold rating to a sell rating in a research note published on Saturday.

A number of other research firms have also recently commented on UPB. Lifesci Capital started coverage on Upstream Bio in a report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price objective on the stock. Evercore downgraded Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price on the stock. in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Finally, Mizuho upgraded Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Upstream Bio presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Upstream Bio Trading Down 11.4%

Upstream Bio stock opened at $8.67 on Friday. The company has a 50-day moving average price of $15.93 and a 200 day moving average price of $21.37. Upstream Bio has a 12-month low of $5.14 and a 12-month high of $33.68. The stock has a market cap of $468.52 million, a P/E ratio of -3.25 and a beta of 2.96.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Thursday, March 26th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.06). Upstream Bio had a negative net margin of 5,026.03% and a negative return on equity of 34.90%. The firm had revenue of $0.67 million during the quarter, compared to analyst estimates of $0.52 million. As a group, analysts forecast that Upstream Bio will post -4.3 EPS for the current year.

Hedge Funds Weigh In On Upstream Bio

A number of hedge funds have recently made changes to their positions in UPB. GF Fund Management CO. LTD. acquired a new stake in Upstream Bio in the 4th quarter valued at approximately $29,000. Torren Management LLC purchased a new position in shares of Upstream Bio during the fourth quarter worth $30,000. Empowered Funds LLC acquired a new stake in shares of Upstream Bio in the fourth quarter valued at $45,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Upstream Bio in the fourth quarter valued at $71,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Upstream Bio by 1,963.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock valued at $57,000 after buying an additional 2,887 shares during the period.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.